Population
T-cells and cell-free system
Design
Preclinical
Authors
Loading...
Nucleolin and YB-1 may be therapeutic targets in T-cell disorders; leaves open translation to human immunity.
Nucleolin and YB-1 are essential RNA-binding proteins for JNK-mediated IL-2 mRNA stabilization during T-cell activation.
Chen et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: